Nancy L. Reinsmoen

TL;DR: Findings suggest that the combination of intravenous immune globulin and rituximab may prove effective as a desensitization regimen for patients awaiting a transplant from either a living donor or a deceased donor.

TL;DR: A clinical definition for AMR (cardiac dysfunction and/or circulating donor-specific antibody) was no longer believed to be required due to recent publications demonstrating that asymptomatic (no cardiac dysfunction) biopsy-proven AMR is associated with subsequent greater mortality and greater development of cardiac allograft vasculopathy.

TL;DR: A working group was created by the International Society for Heart and Lung Transplantation with the aim of determining criteria for pulmonary AMR and establishing a definition, and diagnostic criteria and a working consensus definition were established.

TL;DR: Tocilizumab provides good long‐term outcomes for patients with cAMR and TG, especially compared with historical published treatments, and inhibition of the IL‐6–IL‐6 receptor pathway may represent a novel approach to stabilize allograft function and extend patient lives.

TL;DR: A companion paper to the revised working formulation for the standardization of nomenclature in the diagnosis of heart rejection reviews the published literature documenting the serologic and morphologic evidence that antibody-mediated rejection is clinically significant and associated with graft loss, accelerated transplant-associated coronary artery disease, and death.